Place de l’imagerie moléculaire dans la prise en charge du cancer de la prostate - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Cancer/Radiothérapie Year : 2021

Place de l’imagerie moléculaire dans la prise en charge du cancer de la prostate

Abstract

In the management of prostate cancer in recent years, innovative therapies have appeared requiring precise and reliable disease detection. In 2021, new generation imaging (PET/CT, multiparametric MRI, PET/MRI) have their place at all stages of the prostate cancer natural history to help target the lesion(s) and guide therapy and improve the results obtained. PSMA PET/CT is currently the leader in this type of imaging with a complete offer during the disease: both from diagnosis, to recurrence or in the oligo-metastatic and metastatic stage resistant to castration with a pivotal role in the PSMA theranostic approach. However, multiparametric MRI also has many detection advantages when the prostate is left in place, which suggests the potential major benefit of hybrid PSMA PET/MRI imaging.
Fichier principal
Vignette du fichier
S1761676X20300699.pdf (209.1 Ko) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

inserm-03546721 , version 1 (13-06-2023)

Licence

Attribution - NonCommercial

Identifiers

Cite

Chloé Rousseau, M. Le Thiec, B. Maucherat, M. Frindel, V. Fleury. Place de l’imagerie moléculaire dans la prise en charge du cancer de la prostate. Cancer/Radiothérapie, 2021, 25 (6-7), pp.663-666. ⟨10.1016/j.canrad.2021.07.032⟩. ⟨inserm-03546721⟩
33 View
30 Download

Altmetric

Share

Gmail Facebook X LinkedIn More